High affinity human antibodies to human IL-4 receptor
AssigneeRegeneron Pharmaceuticals, Inc.
InventorsJoel H. Martin, Tammy T. Huang, Jeanette L. Fairhurst, Nicholas J. Papadopoulos
Life of this patent
Estimating the term…
Abstract
The present invention provides methods for treating one or more diseases or disorders which are improved, inhibited or ameliorated by reducing interleukin-4 (IL-4) activity. The methods of the invention comprise administering to a patient an antibody, or antigen-binding fragment thereof, which specifically binds to a human IL-4 receptor.
Claims5
A method of treating asthma, said method comprising administering to a patient in need thereof an antibody or antigen-binding fragment thereof which specifically binds to a human interleukin-4 receptor, wherein said antibody comprises a heavy chain variable region (HCVR) comprising the three heavy chain CDRs (HCDR1, HCDR2 and HCDR3) from SEQ ID NO:162, and a light chain variable region (LCVR) comprising the three light chain CDRs (LCDR1, LCDR2 and LCDR3) from SEQ ID NO:164.
Dependencies are inferred from the claim text.